
















Table 1 Synthesis of the Baylis–Hillman Adducts (continued)

Entry	Ketone	Alkene	Conditions	Product	Yield ^a (%)
3		2a	THF, r.t., 5 d		55
	1c			3ac	
4		2a	THF, r.t., 3 d		56
	1d			3ad	
5		2a	neat, r.t., 24 h		80
	1e			3ae	
6		2a	neat, r.t., 24 h		74
	1f			3af	
7	1a	2b	THF, r.t., 5 d		46
				3ba	
8	1a	2b	neat, r.t., 24 h	3ba	95
9	1b	2b	THF, r.t., 5 d		37
				3bb	
10	1e	2b	neat, r.t., 0.5 h		94
				3be	
11	1f	2b	neat, r.t., 12 h		97
				3bf	
12		2b	THF, r.t., 10 d		36
	1g			3bg	
13	1g	2b	neat, r.t., 2 h	3bg	80


^a The yields refer to isolated and purified products.

The use of excess **2b** led to the formation of compounds **4** through the Baylis–Hillman reaction of intermediates **3gb** with methyl acrylate (Scheme 2).

Spontaneous cyclization of imidazole derivatives **3ba** followed by ester hydrolysis afforded zwitterionic compound **5** in 39% yield (Scheme 3). Apparently spatial



Scheme 2 Reagents and conditions: (i) DABCO, r.t., 7 d.



Scheme 3 Reagents and conditions: (i) KOH, *i*-PrOH–H₂O, 60 °C, 2 h.

preorganization of the nucleophilic nitrogen atom of the imidazole ring and the highly polarized terminal double bond facilitates this cyclization.

Single crystal X-ray analysis unambiguously revealed the structure of compound **5** (Figure 1) as well as the formation of intramolecular hydrogen bond between the hydroxy and carboxy groups.

Compounds **3** readily reacted with various nucleophiles to give Michael addition products. The reaction with aniline **6a** occurred at 60 °C in methanol whereas thiophenol **6b** required suspended potassium hydroxide as base. In the case of phenol, a complex mixture of products was obtained which, according to LC-MS, contained ca. 40% of major compound **8**, which was isolated in 39% yield





Figure 1 Molecular structure of compound **5**; the hydrogen bond is shown as a broken line.



Scheme 4 Reagents and conditions: (i) MeOH, 60 °C, 4 h; (ii) KOH, MeOH, 60 °C, 4 h; (iii) MeOH, r.t., 12 h.

(Scheme 4). The highest yields of the target compounds were attained in the case of the most reactive aliphatic amines **9a–f** and imidazole **9g** (Table 2).⁵

Table 2 Products of Michael Addition Reaction of **3aa** and **3ba**












Entry	Amine	BH adduct	Product	Yield ^a (%)
1	 9a	3aa	 10aa	95
2	9a	3ba	 10ab	88
3	 9b	3ba	 10bb	66
4	 9c	3ba	 10cb	60

Table 2 Products of Michael Addition Reaction of **3aa** and **3ba** (continued)

Entry	Amine	BH adduct	Product	Yield ^a (%)
5	 9d	3ba	 10db	67
6	 9e	3ba	 10eb	83
7	 9f	3ba	 10fb	78
8	 9g	3ba	 10gb	72

^a The yields refer to isolated and purified products.

The structures of all compounds obtained were confirmed by IR, ¹H, ¹³C, and ¹⁹F NMR, and APCI MS data and elemental analysis.

In conclusion, a simple method for the preparation of trifluoromethyl-containing allyl alcohols from 2-(trifluoroacetyl)-1,3-azoles through the Baylis–Hillman reaction was elaborated. We have shown that mild reaction conditions resulted in shorter reaction times and considerably higher yields than the described procedures for the Baylis–Hillman reaction. Compounds **3** readily undergo the Michael addition reaction to give novel functionally diverse druglike heterocycles.

Solvents and other chemicals were used as purchased. Starting materials were purchased (methyl acrylate, acrylonitrile, amines) or prepared (a set of 2-trifluoroacetyl-1,3-azoles).³ Melting points were uncorrected. ¹H, ¹³C, and ¹⁹F NMR spectra were recorded on a Bruker Avance drx 500 instrument at r.t. in DMSO-*d*₆. LC/MS spectra were recorded using an Agilent 1100 Series HPLC equipped with diode-matrix and mass-selective detector Agilent LC/MSD SL. The parameters of chromatography–mass analysis: column, Zorbax SB-C18, 1.8 μm, 4.6 mm × 15 mm; eluent A: MeCN–H₂O with 0.1% of TFA (95:5); eluent B: H₂O with 0.1% of TFA; flow rate, 3 mL/sec; volume of injected sample: 1 μL; UV-detectors at 215, 254, and 265 nm; ionization method: chemical ionization under atmospheric pressure (APCI); ionization mode: simultaneous scanning of positive and negative ions in the mass range of 80–1000 *m/z*. FT-IR spectra were recorded on a Nexus-470 spectrophotometer on samples prepared as KBr discs. Microanalyses were performed in the Microanalytical Laboratory of the Institute of Organic Chemistry, National Academy of Sciences of Ukraine. Satisfactory

microanalyses were obtained for all new substances: C ±0.33; H ±0.45; N ±0.25.

Baylis–Hillman Adducts **3**; General Procedure

To a stirred mixture of an appropriate ketone **1** (1.0 mmol), alkene **2** (1.0 mmol), and THF (1 mL) or without the solvent was added DABCO (0.15 mmol) and stirring continued at r.t. for the specified time. The solvent was removed in vacuo and the residue was washed with H₂O and crystallized (*i*-PrOH).

2-[2,2,2-Trifluoro-1-hydroxy-1-(1-methyl-1H-imidazol-2-yl)ethyl]acrylonitrile (**3aa**)

Colorless crystals; yield: 74%; mp 159–160 °C (dec.).

IR: 3620–3280 (br), 3151, 3132, 2979, 2732, 2233, 1631, 1540, 1485, 1392, 1290, 1240, 1213, 1174, 1157, 1109, 1001, 958, 924, 872, 775, 717, 685, 671 cm^{−1}.

¹H NMR (DMSO-*d*₆): δ = 3.63 (s, 3 H), 6.23 (s, 1 H), 6.66 (s, 1 H), 6.92 (s, 1 H), 7.27 (s, 1 H), 8.25 (s, 1 H).

¹³C NMR (DMSO-*d*₆): δ = 34.68, 75.17 (q, ²*J*_{CF} = 29.3 Hz), 116.38, 120.60, 124.14 (q, ¹*J*_{CF} = 288.0 Hz), 125.38, 127.03, 137.80, 140.17.

¹⁹F NMR (DMSO-*d*₆): δ = −75.51.

MS (APCI): *m/z* = 232 [*M* + 1].

2-[1-(1-Allyl-1H-imidazol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl]acrylonitrile (**3ab**)

Colorless crystals; yield: 62%; mp 127–128 °C.

IR: 3630–3290 (br), 3153, 3116, 2993, 2742, 2642, 2229, 1649, 1620, 1475, 1416, 1402, 1286, 1267, 1201, 1186, 1164, 1142, 1117, 993, 962, 924, 865, 835, 764, 744, 715 cm^{−1}.

^1H NMR (DMSO- d_6): δ = 4.67 (m, 2 H), 5.15 (d, J = 17.0 Hz, 1 H), 5.21 (d, J = 10.5 Hz, 1 H), 5.92 (m, 1 H), 6.28 (s, 1 H), 6.65 (s, 1 H), 6.98 (s, 1 H), 7.25 (s, 1 H), 8.36 (s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 49.31, 75.24 (q, $^2J_{\text{CF}}$ = 29.8 Hz), 116.34, 118.64, 120.85, 123.61, 124.06 (q, $^1J_{\text{CF}}$ = 288.4 Hz), 127.61, 133.87, 137.81, 140.03.

^{19}F NMR (DMSO- d_6): δ = -75.40.

MS (APCI): m/z = 258 [M + 1].

2-[1-(1-Butyl-1*H*-imidazol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl]acrylonitrile (3ac)

Colorless crystals; yield: 55%; mp 134–135 °C.

IR: 3640–3220 (br), 3156, 3134, 2958, 2933, 2875, 2719, 2675, 2623, 2567, 2231, 1621, 1483, 1458, 1396, 1381, 1294, 1242, 1174, 1105, 1005, 960, 926, 874, 773, 746, 710, 677 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 0.88 (t, J = 7.0 Hz, 3 H), 1.27 (m, 2 H), 1.69 (m, 2 H), 3.96 (m, 2 H), 6.25 (s, 1 H), 6.68 (s, 1 H), 6.94 (s, 1 H), 7.35 (s, 1 H), 8.25 (s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 13.94, 19.85, 32.57, 46.59, 75.28 (q, $^2J_{\text{CF}}$ = 28.9 Hz), 116.28, 121.18, 123.36, 124.11 (q, $^1J_{\text{CF}}$ = 288.4 Hz), 127.44, 137.63, 140.03.

^{19}F NMR (DMSO- d_6): δ = -75.34.

MS (APCI): m/z = 274 [M + 1].

MS (IE): m/z (%) = 273 (8) [M] $^+$, 205 (15), 204 (100) [M - CF_3] $^+$, 165 (15), 148 (96), 95 (14), 81 (13), 57 (16), 55 (11), 41 (32).

2-[1-(5-Chloro-1-methyl-1*H*-imidazol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl]acrylonitrile (3ad)

Colorless crystals; yield: 56%; mp 128–129 °C.

IR: 3600–2930 (br), 2754, 2708, 2229, 1655, 1525, 1473, 1450, 1400, 1358, 1279, 1205, 1192, 1182, 1134, 1107, 999, 980, 972, 916, 877, 833, 748, 727, 700, 640 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 3.57 (s, 3 H), 6.31 (s, 1 H), 6.72 (s, 1 H), 7.11 (s, 1 H), 8.44 (s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 32.32, 75.29 (q, $^2J_{\text{CF}}$ = 29.8 Hz), 116.19, 119.90, 120.70, 123.89 (q, $^1J_{\text{CF}}$ = 288.4 Hz), 124.39, 138.57, 140.50.

^{19}F NMR (DMSO- d_6): δ = -75.39.

MS (APCI): m/z = 266 [M + 1].

2-[2,2,2-Trifluoro-1-hydroxy-1-(1-methyl-1*H*-1,2,4-triazol-5-yl)ethyl]acrylonitrile (3ae)

Colorless crystals; yield: 80%; mp 129–130 °C.

IR: 3630–3305 (br), 3124, 2924, 2769, 2723, 2237, 1630, 1491, 1458, 1439, 1408, 1389, 1281, 1248, 1190, 1115, 1001, 984, 941, 908, 879, 731, 706, 675 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 3.88 (s, 3 H), 6.40 (s, 1 H), 6.77 (s, 1 H), 8.05 (s, 1 H), 8.74 (s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 37.91, 74.36 (q, $^2J_{\text{CF}}$ = 30.2 Hz), 115.90, 119.13, 123.72 (q, $^1J_{\text{CF}}$ = 288.0 Hz), 138.93, 148.90, 150.27.

^{19}F NMR (DMSO- d_6): δ = -75.74.

MS (APCI): m/z = 231 [M - 1].

2-[2,2,2-Trifluoro-1-hydroxy-1-(4-methylthiazol-2-yl)ethyl]acrylonitrile (3af)

Yellow oil; yield: 74%.

IR: 3600–3170 (br), 3120, 2931, 2237, 1659, 1527, 1446, 1396, 1273, 1244, 1190, 1174, 1126, 1092, 968, 893, 872, 746 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 2.40 (s, 3 H), 6.57 (s, 1 H), 6.70 (s, 1 H), 7.49 (s, 1 H), 8.76 (s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 17.32, 76.69 (q, $^2J_{\text{CF}}$ = 30.2 Hz), 116.41, 117.80, 120.67, 123.65 (q, $^1J_{\text{CF}}$ = 288.0 Hz), 137.97, 153.25, 165.00.

^{19}F NMR (DMSO- d_6): δ = -81.41.

MS (APCI): m/z = 249 [M + 1].

Methyl 2-[2,2,2-Trifluoro-1-hydroxy-1-(1-methyl-1*H*-imidazol-2-yl)ethyl]acrylate (3ba)

Colorless crystals; yield: 95%; mp 106–107 °C.

IR: 3560–3300 (br), 3155, 3124, 3020, 2966, 2726, 2663, 2588, 1736, 1631, 1535, 1481, 1446, 1389, 1321, 1269, 1250, 1184, 1171, 1130, 1113, 1103, 1055, 999, 960, 949, 920, 856, 814, 760, 733, 710, 690, 665, 627, 596 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 3.56 (s, 3 H), 3.58 (s, 3 H), 6.18 (s, 1 H), 6.43 (s, 1 H), 6.81 (s, 1 H), 7.12 (s, 1 H), 7.57 (s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 34.32, 52.50, 75.14 (q, $^2J_{\text{CF}}$ = 28.9 Hz), 124.11, 124.56 (q, $^1J_{\text{CF}}$ = 288.0 Hz), 126.26, 129.34, 137.67, 141.99, 165.33.

^{19}F NMR (DMSO- d_6): δ = -74.88.

MS (APCI): m/z = 265 [M + 1].

Methyl 2-[1-(1-Allyl-1*H*-imidazol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl]acrylate (3bb)

Colorless crystals; yield: 37%; mp 103–104 °C.

IR: 3600–3200 (br), 3155, 3131, 3028, 2958, 2804–2495 (br), 1741, 1630, 1477, 1444, 1392, 1321, 1267, 1169, 1105, 1001, 958, 920, 812, 760, 671 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 3.53 (s, 3 H), 4.63 (m, 2 H), 5.13 (m, 2 H), 5.88 (s, 1 H), 6.20 (s, 1 H), 6.45 (s, 1 H), 6.85 (s, 1 H), 7.07 (s, 1 H), 7.64 (s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 49.09, 52.42, 75.30 (q, $^2J_{\text{CF}}$ = 28.9 Hz), 118.07, 122.31, 124.516 (q, $^1J_{\text{CF}}$ = 288.0 Hz), 126.92, 129.66, 134.44, 137.80, 141.81, 165.10.

^{19}F NMR (DMSO- d_6): δ = -75.19.

MS (APCI): m/z = 291 [M + 1].

Methyl 2-[2,2,2-Trifluoro-1-hydroxy-1-(1-methyl-1*H*-1,2,4-triazol-5-yl)ethyl]acrylate (3be)

Colorless crystals; yield: 94%; mp 75–76 °C.

IR: 3600–3300 (br), 3140, 3124–2980 (br), 2964, 2777, 1736, 1630, 1506, 1466, 1456, 1443, 1385, 1321, 1271, 1194, 1182, 1161, 1119, 1026, 1001, 962, 931, 899, 858, 816, 787, 715, 671, 588 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 3.56 (s, 3 H), 3.80 (s, 3 H), 6.38 (s, 1 H), 6.58 (s, 1 H), 7.87 (s, 1 H), 8.05 (br s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 37.35, 52.59, 74.18 (q, $^2J_{\text{CF}}$ = 30.2 Hz), 124.19 (q, $^1J_{\text{CF}}$ = 288.0 Hz), 130.60, 136.30, 149.51, 150.57, 164.71.

^{19}F NMR (DMSO- d_6): δ = -75.15.

MS (APCI): m/z = 266 [M + 1].

Methyl 2-[2,2,2-Trifluoro-1-hydroxy-1-(4-methylthiazol-2-yl)ethyl]acrylate (3bf)

Colorless oil; yield: 97%.

IR: 3600–3150 (br), 3120, 2958, 2929, 2856, 1733, 1693, 1618, 1529, 1443, 1329, 1265, 1194, 1173, 1136, 980, 962, 885, 818, 744, 619 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 2.31 (s, 3 H), 3.55 (s, 3 H), 6.22 (s, 1 H), 6.48 (s, 1 H), 7.33 (s, 1 H), 8.01 (br s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 17.29, 52.44, 77.05 (q, $^2J_{\text{CF}}$ = 28.9 Hz), 116.77, 124.21 (q, $^1J_{\text{CF}}$ = 288.0 Hz), 129.40, 137.48, 152.10, 164.96, 167.73.

^{19}F NMR (DMSO- d_6): δ = -73.89.

MS (APCI): m/z = 282 [M + 1].

Methyl 2-[1-(Benzothiazol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl]acrylate (3bg)

Colorless crystals; yield: 80%; mp 45–46 °C.

IR: 3250 (br), 3140, 2958, 2926, 2854, 1695, 1616, 1514, 1444, 1417, 1325, 1259, 1186, 1176, 1149, 995, 968, 904, 831, 818, 766, 741, 731, 634 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 3.54 (s, 3 H), 6.37 (s, 1 H), 6.63 (s, 1 H), 7.47 (dd, J = 8.0, 7.0 Hz, 1 H), 7.52 (dd, J = 8.0, 7.0 Hz, 1 H), 8.02 (d, J = 8.0 Hz, 1 H), 8.13 (d, J = 8.0 Hz, 1 H), 8.32 (s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 52.52, 77.54 (q, $^2J_{\text{CF}}$ = 28.9 Hz), 122.68, 123.64, 124.27 (q, $^1J_{\text{CF}}$ = 288.0 Hz), 126.08, 126.66, 130.02, 135.63, 137.13, 152.84, 164.61, 170.92.

^{19}F NMR (DMSO- d_6): δ = -74.94.

MS (APCI): m/z = 318 [M + 1].

Dimethyl 2-[1-(Benzothiazol-2-yl)-2,2,2-trifluoro-1-hydroxyethyl]-4-methylene pentanedioate (4)

Colorless crystals; yield: 40%; mp 122–123 °C.

IR: 3340 (br), 3078, 3001, 2951, 2855, 1727, 1698, 1635, 1502, 1446, 1438, 1378, 1340, 1317, 1294, 1251, 1236, 1188, 1170, 1141, 1033, 960, 893, 819, 765, 735, 685, 607 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 2.80–2.93 (m, 2 H), 3.25 (s, 3 H), 3.70 (s, 3 H), 3.80 (m, 1 H), 5.62 (s, 1 H), 6.10 (s, 1 H), 7.46 (dd, J = 8.0, 7.0 Hz, 1 H), 7.52 (dd, J = 8.0, 7.0 Hz, 1 H), 8.04 (d, J = 8.0 Hz, 1 H), 8.12 (d, J = 8.0 Hz, 1 H), 8.13 (s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 29.57, 50.73, 51.84, 52.46, 78.31 (q, $^2J_{\text{CF}}$ = 28.1 Hz), 122.74, 123.67, 124.60 (q, $^1J_{\text{CF}}$ = 289.2 Hz), 126.14, 126.86, 128.12, 135.10, 137.00, 153.27, 166.58, 170.11, 170.97.

^{19}F NMR (DMSO- d_6): δ = -74.84.

MS (APCI): m/z = 404 [M + 1].

7-Hydroxy-1-methyl-7-(trifluoromethyl)-1,5,6,7-tetrahydro-pyrrolo[1,2-*a*]imidazol-4-ium-6-carboxylate (5)

Compound **3ba** (3 mmol) was dissolved in *i*-PrOH (2 mL), a soln of KOH (0.1 mmol) in H_2O (1 mL) was added. The mixture was stirred at 60 °C for 2 h. The solvent was removed in vacuo, the residue was recrystallized (*i*-PrOH) to give **5** as colorless crystals; yield: 39%; mp 206–207 °C (dec).

IR: 3650–3200 (br), 3109, 3043, 3020, 2980, 1578, 1460, 1441, 1363, 1313, 1250, 1203, 1169, 1149, 1070, 987, 947, 818, 687, 623, 588, 519, 449 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 3.50 (d, J = 8.0 Hz, 1 H), 3.88 (s, 3 H), 4.49 (dd, J = 11.5, 8.0 Hz, 1 H), 4.75 (d, J = 11.5 Hz, 1 H), 7.81 (s, 1 H), 7.82 (s, 1 H), 13.99 (s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 34.91, 46.38, 50.89, 77.28 (q, $^2J_{\text{CF}}$ = 31.9 Hz), 119.84, 124.85 (q, $^1J_{\text{CF}}$ = 285.5 Hz), 129.92, 145.61, 170.44.

^{19}F NMR (DMSO- d_6): δ = -79.91.

MS (APCI): m/z = 251 [M+1].

Methyl 2-(Anilinomethyl)-4,4,4-trifluoro-3-hydroxy-3-(1-methyl-1*H*-imidazol-2-yl)butanoate (7a)

A mixture of aniline (1.0 mmol), **3ba** (1.0 mmol), and MeOH (1 mL) was stirred at 60 °C for 4 h. The solvent was removed in vacuo,

the residue was recrystallized (*i*-PrOH) to give **7a** as colorless crystals; yield: 38%; mp 152–153 °C.

IR: 3367 (br), 3257, 3140, 3118, 3055, 3035, 3010, 2956, 2927, 2872, 1711, 1605, 1539, 1500, 1485, 1470, 1439, 1383, 1356, 1300, 1269, 1238, 1209, 1196, 1173, 1130, 982, 964, 906, 750, 708, 692, 592, 575 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 2.96 (m, 1 H), 3.56 (m, 1 H), 3.60 (s, 3 H), 3.82 (s, 3 H), 4.01 (m, 1 H), 5.73 (m, 1 H), 6.51 (t, J = 7.5 Hz, 1 H), 6.66 (d, J = 7.5 Hz, 2 H), 6.93 (s, 1 H), 6.99 (s, 1 H), 7.03 (dd, J = 7.5 Hz, 2 H), 7.20 (s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 35.90, 42.61, 48.88, 52.27, 77.75 (q, $^2J_{\text{CF}}$ = 28.5 Hz), 112.77, 116.46, 124.97 (q, $^1J_{\text{CF}}$ = 288.0 Hz), 125.64, 127.15, 129.27, 140.78, 148.97, 171.63.

^{19}F NMR (DMSO- d_6): δ = -76.34.

MS (APCI): m/z = 358 [M + 1].

Methyl 4,4,4-Trifluoro-3-hydroxy-3-(1-methyl-1*H*-imidazol-2-yl)-2-[(phenylsulfanyl)methyl]butanoate (7b)

A mixture of PhSH (1.0 mmol), KOH (0.1 mmol), **3ba** (1.0 mmol), and MeOH (1 mL) was stirred at 60 °C for 4 h. CH_2Cl_2 was added, the organic phase was washed with H_2O and concentrated in vacuo. Product was purified by flash chromatography to give **7b** as a colorless oil; yield: 49%.

IR: 3600–3200 (br), 3114, 3059, 3005, 2954, 1713, 1583, 1524, 1483, 1441, 1352, 1279, 1217, 1165, 1122, 1088, 1054, 1026, 1011, 964, 901, 833, 744, 690, 652 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 2.96 (d, J = 13.5 Hz, 1 H), 3.20 (dd, J = 13.5, 12.0 Hz, 1 H), 3.62 (s, 3 H), 3.79 (s, 3 H), 3.89 (d, J = 12.0 Hz, 1 H), 6.95 (s, 1 H), 7.16 (s, 1 H), 7.17–7.23 (m, 2 H), 7.28–7.38 (m, 4 H).

^{13}C NMR (DMSO- d_6): δ = 31.29, 35.78, 49.99, 52.32, 78.42 (q, $^2J_{\text{CF}}$ = 28.9 Hz), 124.77 (q, $^1J_{\text{CF}}$ = 288.0 Hz), 125.77, 126.54, 127.20, 128.84, 129.49, 135.39, 140.45, 170.66.

^{19}F NMR (DMSO- d_6): δ = -76.08.

MS (APCI): m/z = 375 [M + 1].

Methyl 4,4,4-Trifluoro-3-hydroxy-2-(methoxymethyl)-3-(1-methyl-1*H*-imidazol-2-yl)butanoate (8)

A mixture of **3ba** (1.0 mmol), KOH (1.0 mmol), and MeOH (1 mL) was stirred at 60 °C for 4 h. The solvent was removed in vacuo, the residue was recrystallized (*i*-PrOH) to give **8** as colorless crystals; yield: 39%; mp 79–80 °C.

IR: 3670–3150 (br), 3138, 3003, 2956, 2918, 1740, 1484, 1439, 1360, 1290, 1242, 1209, 1188, 1163, 1120, 1068, 995, 966, 941, 914, 764, 712, 661 cm^{-1} .

^1H NMR (DMSO- d_6): δ = 3.14 (s, 3 H), 3.27 (dd, J = 9.5, 3.0 Hz, 1 H), 3.63 (s, 3 H), 3.70 (dd, J = 10.5, 9.5 Hz, 1 H), 3.76 (s, 3 H), 3.85 (dd, J = 10.5, 3.0 Hz, 1 H), 6.90 (s, 1 H), 6.97 (s, 1 H), 7.16 (s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 35.77, 49.77, 52.25, 58.72, 70.76, 77.10 (q, $^2J_{\text{CF}}$ = 28.9 Hz), 124.81 (q, $^1J_{\text{CF}}$ = 288.4 Hz), 125.45, 127.13, 140.47, 171.20.

^{19}F NMR (DMSO- d_6): δ = -76.40.

MS (APCI): m/z = 297 [M + 1].

Michael Addition of Secondary Amines; General Procedure

A mixture of amine (1.0 mmol), **3** (1.0 mmol), and MeOH (1 mL) was stirred at r.t. for 12 h. The solvent was removed in vacuo, the residue was recrystallized (*i*-PrOH).

4,4,4-Trifluoro-3-hydroxy-3-(1-methyl-1*H*-imidazol-2-yl)-2-(pyrrolidin-1-ylmethyl)butanenitrile (10aa)

Colorless crystals; yield: 95%; mp 131 °C.

IR: 3670–3170 (br), 3124, 2941, 2864, 2243, 1473, 1408, 1348, 1254, 1184, 1155, 1136, 1119, 1003, 976, 947, 906, 887, 756, 685, 453 cm⁻¹.

¹H NMR (DMSO-*d*₆): δ = 1.68 (m, 4 H), 2.39 (m, 2 H), 2.46 (m, 1 H), 2.60 (m, 2 H), 3.09 (m, 1 H), 3.79 (s, 3 H), 4.13 (m, 1 H), 6.91 (s, 1 H), 7.19 (s, 1 H), 8.47 (s, 1 H).

¹³C NMR (DMSO-*d*₆): δ = 23.71, 35.65, 36.40, 54.14, 54.44, 77.58 (q, ²*J*_{CF} = 28.9 Hz), 118.93, 124.52 (q, ¹*J*_{CF} = 288.0 Hz), 125.80, 127.19, 140.00.

¹⁹F NMR (DMSO-*d*₆): δ = -75.52.

MS (APCI): *m/z* = 303 [M + 1].

Methyl 4,4,4-Trifluoro-3-hydroxy-3-(1-methyl-1*H*-imidazol-2-yl)-2-(pyrrolidin-1-ylmethyl)butanoate (10ab)

Colorless crystals; yield: 88%; mp 115–116 °C.

IR: 3650–3170 (br), 3154, 3106, 3026, 2968, 2879, 2827, 2783, 2748, 1743, 1730, 1529, 1479, 1444, 1437, 1356, 1284, 1176, 1138, 1117, 1055, 987, 962, 951, 931, 906, 889, 791, 764, 712, 687, 588, 548, 509, 498 cm⁻¹.

¹H NMR (DMSO-*d*₆): δ = 1.60 (m, 4 H), 2.12 (d, *J* = 10.5 Hz, 1 H), 2.27 (m, 2 H), 2.46 (m, 2 H), 3.09 (dd, *J* = 10.5, 9.5 Hz, 1 H), 3.61 (s, 3 H), 3.78 (s, 3 H), 3.84 (d, *J* = 9.5 Hz, 1 H), 6.88 (s, 1 H), 6.98 (s, 1 H), 7.13 (s, 1 H).

¹³C NMR (DMSO-*d*₆): δ = 23.65, 35.78, 48.74, 52.10, 54.08, 54.68, 77.86 (q, ²*J*_{CF} = 28.9 Hz), 124.97 (q, ¹*J*_{CF} = 288.0 Hz), 125.23, 127.03, 140.86, 171.99.

¹⁹F NMR (DMSO-*d*₆): δ = -76.26.

MS (APCI): *m/z* = 336 [M + 1].

Methyl 4,4,4-Trifluoro-3-hydroxy-3-(1-methyl-1*H*-imidazol-2-yl)-2-(piperidin-1-ylmethyl)butanoate (10bb)

Colorless crystals; yield: 66%; mp 101–102 °C.

IR: 3630–3150 (br), 2937, 2852, 1743, 1732, 1477, 1437, 1363, 1304, 1284, 1200, 1167, 1130, 1057, 968, 931, 906, 762, 669, 417 cm⁻¹.

¹H NMR (DMSO-*d*₆): δ = 1.30 (m, 2 H), 1.38 (m, 4 H), 2.09 (m, 2 H), 2.15 (d, *J* = 11.5 Hz, 1 H), 2.43 (m, 2 H), 2.79 (dd, *J* = 11.5 Hz, 1 H), 3.61 (s, 3 H), 3.77 (s, 3 H), 3.85 (d, *J* = 11.5 Hz, 1 H), 6.88 (s, 1 H), 7.05 (s, 1 H), 7.13 (s, 1 H).

¹³C NMR (DMSO-*d*₆): δ = 24.27, 26.14, 35.75, 47.20, 52.03, 54.69, 57.20, 77.73 (q, ²*J*_{CF} = 28.9 Hz), 124.97 (q, ¹*J*_{CF} = 288.0 Hz), 125.22, 127.01, 140.81, 172.03.

¹⁹F NMR (DMSO-*d*₆): δ = -76.27.

MS (APCI): *m/z* = 350 [M + 1].

Methyl 4,4,4-Trifluoro-3-hydroxy-3-(1-methyl-1*H*-imidazol-2-yl)-2-(morpholin-4-ylmethyl)butanoate (10cb)

Colorless crystals; yield: 60%; mp 118–119 °C.

IR: 3670–3190 (br), 3118, 3097, 2999, 2954, 2877, 2852, 2827, 2777, 2688, 1724, 1524, 1485, 1439, 1360, 1338, 1296, 1244, 1211, 1196, 1176, 1142, 1117, 984, 964, 930, 914, 901, 876, 793, 712, 673, 552, 457 cm⁻¹.

¹H NMR (DMSO-*d*₆): δ = 2.05–2.19 (m, 3 H), 2.40–2.47 (m, 2 H), 2.84 (dd, *J* = 11.8 Hz, 1 H), 3.37–3.54 (m, 4 H), 3.63 (s, 3 H), 3.77 (s, 3 H), 3.90 (dd, *J* = 11.0, 3.5 Hz, 1 H), 6.87 (s, 1 H), 6.89 (s, 1 H), 7.14 (s, 1 H).

¹³C NMR (DMSO-*d*₆): δ = 35.84, 47.14, 52.16, 53.92, 57.05, 66.73, 77.62 (q, ²*J*_{CF} = 28.5 Hz), 124.96 (q, ¹*J*_{CF} = 288.0 Hz), 125.39, 127.10, 140.69, 171.89.

¹⁹F NMR (DMSO-*d*₆): δ = -76.36.

MS (APCI): *m/z* = 352 [M + 1].

Methyl 4,4,4-Trifluoro-3-hydroxy-3-(1-methyl-1*H*-imidazol-2-yl)-2-[(4-methylpiperazin-1-yl)methyl]butanoate (10db)

Colorless crystals; yield: 67%; mp 106–107 °C.

IR: 3670–3150 (br), 3097, 2966, 2953, 2931, 2883, 2848, 2829, 2802, 2775, 1724, 1524, 1479, 1456, 1439, 1356, 1336, 1288, 1252, 1221, 1194, 1174, 1130, 1092, 1012, 985, 962, 928, 901, 870, 812, 785, 679, 621, 567 cm⁻¹.

¹H NMR (DMSO-*d*₆): δ = 2.05 (s, 3 H), 2.11–2.30 (m, 6 H), 2.42–2.52 (m, 2 H), 2.84 (dd, *J* = 11.8 Hz, 1 H), 3.62 (s, 3 H), 3.77 (s, 3 H), 3.86 (m, 1 H), 6.88 (s, 1 H), 6.39 (s, 1 H), 7.13 (s, 1 H).

¹³C NMR (DMSO-*d*₆): δ = 35.81, 46.08, 47.31, 52.09, 53.26, 55.22, 56.48, 77.68 (q, ²*J*_{CF} = 28.5 Hz), 124.97 (q, ¹*J*_{CF} = 288.0 Hz), 125.31, 127.09, 140.74, 171.95.

¹⁹F NMR (DMSO-*d*₆): δ = -76.36.

MS (APCI): *m/z* = 365 [M + 1].

Methyl 4,4,4-Trifluoro-3-hydroxy-3-(1-methyl-1*H*-imidazol-2-yl)-2-[(4-phenylpiperazin-1-yl)methyl]butanoate (10eb)

Colorless crystals; yield: 83%; mp 113–114 °C.

IR: 3670–3140 (br), 2960, 2854, 2812, 1724, 1603, 1504, 1481, 1446, 1387, 1354, 1279, 1261, 1238, 1169, 1122, 1011, 984, 953, 931, 764, 692, 675, 517 cm⁻¹.

¹H NMR (DMSO-*d*₆): δ = 2.21 (m, 1 H), 2.30 (m, 2 H), 2.63 (m, 2 H), 2.93 (dd, *J* = 12.0 Hz, 1 H), 3.02 (m, 4 H), 3.63 (s, 3 H), 3.78 (s, 3 H), 3.94 (m, 1 H), 6.74 (t, *J* = 7.0 Hz, 1 H), 6.85–6.95 (m, 4 H), 7.13–7.22 (m, 3 H).

¹³C NMR (DMSO-*d*₆): δ = 35.84, 47.37, 48.78, 52.14, 53.35, 56.56, 77.67 (q, ²*J*_{CF} = 28.5 Hz), 115.79, 119.24, 124.99 (q, ¹*J*_{CF} = 288.0 Hz), 125.37, 127.13, 129.30, 140.74, 151.41, 172.00.

¹⁹F NMR (DMSO-*d*₆): δ = -76.34.

MS (APCI): *m/z* = 427 [M + 1].

Methyl 2-[(4-Benzylpiperazin-1-yl)methyl]-4,4,4-trifluoro-3-hydroxy-3-(1-methyl-1*H*-imidazol-2-yl)butanoate (10fb)

Colorless crystals; yield: 78%; mp 117–118 °C.

IR: 3650–3160 (br), 3086, 3032, 2947, 2810, 2767, 1741, 1477, 1456, 1437, 1362, 1294, 1286, 1201, 1165, 1122, 1012, 966, 933, 904, 760, 741, 696 cm⁻¹.

¹H NMR (DMSO-*d*₆): δ = 2.10–2.39 (m, 7 H), 2.50–2.52 (m, 2 H), 2.84 (dd, *J* = 12.0 Hz, 1 H), 3.40 (m, 2 H), 3.61 (s, 3 H), 3.77 (s, 3 H), 3.86 (m, 1 H), 6.88 (s, 1 H), 6.94 (s, 1 H), 7.13 (s, 1 H), 7.18–7.33 (m, 5 H).

¹³C NMR (DMSO-*d*₆): δ = 35.78, 47.29, 52.08, 53.13, 53.43, 56.54, 62.45, 77.68 (q, ²*J*_{CF} = 27.7 Hz), 124.97 (q, ¹*J*_{CF} = 288.0 Hz), 125.29, 127.05, 127.27, 128.53, 129.18, 138.67, 140.73, 171.94.

¹⁹F NMR (DMSO-*d*₆): δ = -76.30.

MS (APCI): *m/z* = 441 [M + 1].

Methyl 4,4,4-Trifluoro-3-hydroxy-2-(1*H*-imidazol-1-ylmethyl)-3-(1-methyl-1*H*-imidazol-2-yl)butanoate (10gb)

Colorless crystals; yield: 72%; mp 131–132 °C.

IR: 3610, 3500–3300 (br), 3259, 3136, 3116, 2954, 1732, 1514, 1479, 1435, 1360, 1275, 1252, 1219, 1169, 1136, 1107, 1092, 987, 966, 947, 763, 660 cm⁻¹.

¹H NMR (DMSO-*d*₆): δ = 3.54 (s, 3 H), 3.82 (s, 3 H), 3.95 (d, *J* = 12.0 Hz, 1 H), 4.09 (d, *J* = 11.0 Hz, 1 H), 4.41 (dd, *J* = 12.0, 11.0 Hz, 1 H), 6.87 (s, 1 H), 7.00 (s, 1 H), 7.01 (s, 1 H), 7.24 (s, 1 H), 7.44 (s, 1 H), 7.51 (br s, 1 H).

^{13}C NMR (DMSO- d_6): δ = 35.85, 45.77, 51.96, 52.66, 77.60 (q, $^2J_{\text{CF}}$ = 30.2 Hz), 119.50, 124.69 (q, $^1J_{\text{CF}}$ = 288.0 Hz), 125.98, 127.44, 129.35, 137.85, 140.24, 170.38.

^{19}F NMR (DMSO- d_6): δ = -76.01.

MS (APCI): m/z = 333 [M + 1].

Single crystal X-ray analysis: Unit cell parameters and intensities of all sets of reflections were measured using an Xcalibur-3 diffractometer (CCD detector, $\lambda(\text{MoK}\alpha)$ irradiation, ω -scans) All structures were solved by direct method using the SHELXTL package.⁶ The positions of the hydrogen atoms were located from difference maps of the electron density and refined as riding atoms. Atomic coordinates and crystallographic parameters were deposited at the Cambridge Crystallographic Data Centre under CCDC 687052.

Crystal data for 5: $\text{C}_9\text{H}_9\text{F}_3\text{N}_2\text{O}_3$, triclinic, $P\bar{1}$, a = 6.619(2) Å, b = 8.654(5) Å, c = 10.160(3) Å, α = 107.15(4)°, β = 92.01(2)°, γ = 111.11(4)°, V = 512.2(4) Å³, Z = 2, ρ_{calcd} = 1.62 g/cm³, μ = 0.156 mm⁻¹, $F(000)$ = 256, 159 parameters, $R1$ = 0.0317, $wR2$ = 0.0791 (1284 reflections, $F > 4\sigma$), $R1$ = 0.0451, $wR2$ = 0.0842 (1702 unique reflections), S = 0.987, $\Delta\rho$ (min/max) = -0.202/0.191 e Å⁻³.

References

- (1) (a) Basavaiah, D.; Venkateswara Rao, K.; Reddy, R. J. *Chem. Soc. Rev.* **2007**, 36, 1581. (b) Basavaiah, D.; Jaganmohan Rao, A.; Satyanarayana, T. *Chem. Rev.* **2003**, 103, 811.
- (2) (a) CF₃ Ketones: Golubev, A. S.; Kolomiets, A. F.; Fokin, A. V. *J. Fluorine Chem.* **1991**, 54, 272. (b) Isatins, ninhydrin: Chung, Y. M.; Im, Y. J.; Kim, J. N. *Bull. Korean Chem. Soc.* **2002**, 23, 1651.
- (3) Common ketones: Hill, J. S.; Isaacs, N. S. *Tetrahedron Lett.* **1986**, 27, 5007.
- (4) Khodakovskiy, P. V.; Volochnyuk, D. M.; Panov, D. M.; Pervak, I. I.; Zarudnitskii, E. V.; Shishkin, O. V.; Yurchenko, A. A.; Shivanyuk, A.; Tolmachev, A. A. *Synthesis* **2008**, 948.
- (5) For analogous transformation of BH products see: Batra, S.; Roy, A. K.; Patra, A.; Bhaduri, A. P.; Surin, W. R.; Raghavan, S. A. V.; Sharma, P.; Kapoor, K.; Dikshit, M. *Bioorg. Med. Chem.* **2004**, 12, 2059.
- (6) Sheldrick, G. M. SHELXTL PLUS, PC Version; a system of computer programs for the determination of crystal structure from X-ray diffraction data; Rev.5.1, 1998.